Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Two Contract Research Sites Over Protocol Violations

Executive Summary

Comprehensive Clinical Research has made several personnel changes in response to an FDA inspection that resulted in a June 5 warning letter

You may also be interested in...



Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says

Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.

Roche Tamiflu Labeled For Seasonal Prophylaxis With 42-Day Dosing Regimen

Roche/Gilead Tamiflu updated labeling includes data from a seasonal prophylaxis study in elderly nursing home residents who took oseltamivir for 42 days.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS040044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel